Trump Executive Order Tracker

This Executive Order instructs federal agencies to accelerate research, review, and potential approval pathways for psychedelic drugs intended to treat serious mental illnesses, including major depressive disorder and substance abuse disorder. The EO directs FDA to prioritize review of qualifying products with Breakthrough Therapy designation through the National Priority Voucher Program and to facilitate access to psychedelic drugs under the federal Right to Try Act. The EO tasks HHS to allocate at least $50 million through ARPA‑H to support federal collaboration with states that have enacted or are developing psychedelic drugs for serious mental illnesses. It also instructs HHS, FDA, and the VA, in collaboration with the private sector, to increase clinical trial preparation, data sharing, and real‑world evidence generation regarding psychedelic drugs – prioritizing drugs with Breakthrough Therapy designation – and requires DOJ and HHS to expedite rescheduling review for products that successfully complete Phase 3 trials and receive FDA approval.

This establishes the White House Great American Recovery Initiative (“Initiative”) co-chaired by the Secretary of Health and Human Services and the Senior Advisor for Addiction Recovery. The Initiative will have an Executive Director who will administer and execute the day-to-day operations of the Initiative. The Co-Chairs and the Executive Director, along with the other members of the Initiative, shall: recommend all necessary steps to coordinate the Federal Government’s response to the addiction crisis; increase awareness of the disease of addiction; advise agency heads on how to implement programs that address addiction efforts; advise agency heads on directing grants to support addiction recovery; and consult with States, tribal nations, local jurisdictions, and other organizations on strategies to address treatment and recovery.

This order directs the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act. Schedule III drugs are classified as having a potential for abuse less than those drugs in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.

This memorandum directs the Secretary of Health and Human Services and the Director of the Centers for Disease Control and Prevention to review best practices from peer, developed countries for core childhood vaccination recommendations. If those best practices are found superior to the United States’s current recommendations, they are further directed to update the U.S. core childhood vaccine schedule while preserving access to existing vaccines.

Directs the Department of Health and Human Services (HHS) to modernize the nation's child-welfare system by improving data collection, updating state systems, expanding the use of advanced technology, and publishing annual performance scorecards. Establishes the "Fostering the Future" initiative to create new education, employment, and support pathways for youth in or transitioning out of foster care while expanding partnerships with faith-based organizations. 

This order directs the MAHA Commission, in coordination with the Secretary of HHS, the Assistant to the President for Science and Technology (APST), and the Special Advisor for AI and Crypto to develop innovative ways to utilize advanced technologies such as AI to unlock improved diagnoses, treatments, cures, and prevention strategies for pediatric cancer. The initial focus will be to identify opportunities to accelerate the progress of AI-driven solutions at the Childhood Cancer Data Initiative (CCDI) and fund research projects at National Cancer Institute-Designated Cancer Centers that utilize and incorporate AI in their research and analysis.
 
The order calls for increased investment and engagement in pediatric cancer care and research from both the public and private sector. The order requires that the Secretary of HHS and the ASPT ensure that AI innovation is integrated into current work on interoperability.

Renews 22 federal advisory committees across multiple agencies through September 30, 2027. Assigns responsibility for each committee to the relevant agency head and replaces earlier committee renewal provisions from Executive Order 14109 of September 29, 2023.  

The Executive Order aims to bolster the resilience of the United States’s pharmaceutical supply chain by stockpiling Active Pharmaceutical Ingredients (“APIs”) for critical medicines in the Strategic Active Pharmaceutical Ingredients Reserve (“SAPIR”) and encouraging the domestic production and procurement of such APIs.

Reestablishes the Presidential Fitness Test and revitalizes the President's Council on Sports, Fitness, and Nutrition to promote youth participation in sports, improve national health, and address rising rates of obesity and inactivity. Directs federal agencies to support these initiatives and outlines strategies for nationwide engagement and fitness programming.
 
This executive order reestablishes the Presidential Fitness Test and revitalizes the President's Council on Sports, Fitness, and Nutrition to address the national health crisis and promote youth participation in sports. It directs the Secretary of Health and Human Services, in coordination with the Secretary of Education, to administer the test and support the Council's initiatives, which include developing school-based fitness programs, setting national youth fitness programs, setting goals, and launching public campaigns. The Council is also tasked with advising the President on strategies to combat childhood obesity and inactivity, enhance military readiness, and foster a culture of physical excellence across all sectors of society.